Previous 10 | Next 10 |
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval (PMA) supplement with the FDA for its newly developed, long-lived, non-rechargeable ...
Inflation is here; and that means these groups ought to be on your radar. The best stocks within every sector now. Over 20 new stocks join our 'best stocks' list this week. For further details see: The Stocks To Focus On Today
Axonics (AXNX) has received FDA approval allowing the use of detachable extremity coils for patients undergoing 1.5T and 3.0T MRI scans. The FDA previously approved 1.5T and 3.0T MRI conditional labeling for using head and full-body transmit coils for the implantable components of the Axonics...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has received FDA approval allowing the use of detachable extremity coils for patients undergoing 1.5T and 3.0T MRI ...
Axonics (AXNX) announces European CE Mark approval of its second generation Axonics r-SNM implantable neurostimulator ((INS)) and wireless patient remote control with SmartMRI technology. Axonics previously received FDA approval for this INS and remote control during 2020. This version r...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced European CE Mark approval of its second generation Axonics r-SNM ® implantable neurostimul...
Axonics (AXNX) has priced its public offering of 3.5M common shares at $50.00/share, for expected gross proceeds of $175M.Underwriters' over-allotment is an additional 525K shares. Net proceeds will be used to repay outstanding indebtedness, for commercialization purpose, R&D activities, ...
Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the pricing of its public offering of 3,500,000 shares of its common s...
Axonics (AXNX) announces that it has commenced a proposed public offering of $150M in shares.Expects to grant the underwriters a 30-day option to purchase up to $22.5M in additional shares.Axonics anticipates using net proceeds to repay all or a portion of its outstanding indebtedness of $75M...
Axonics, Inc. (AXNX) Q1 2021 Earnings Conference Call May 06, 2021 4:30 PM ET Company Participants Neil Bhalodkar – Investor Relations Raymond Cohen – Chief Executive Officer Dan Dearen – President and Chief Financial Officer Conference Call Participants Bob Hopkins ...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...